Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cystemustine

Drug Profile

Cystemustine

Alternative Names: CMSO2EN2

Latest Information Update: 31 Oct 2002

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Nitrosourea compounds; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Colorectal cancer; Glioma; Head and neck cancer; Malignant melanoma; Renal cancer; Sarcoma

Most Recent Events

  • 23 Mar 2000 A phase II study in melanoma has been added to the therapeutic trials and adverse events sections
  • 03 Aug 1999 Preclinical studies have been added to the pharmacodynamics section
  • 19 May 1997 Phase-II clinical trials for Glioma in France (Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top